Roche signs deal with Skyhawk over molecules that modulate RNA splicing

pharmafile | July 17, 2019 | News story | Research and Development Genentech, Roche, Skyhawk, drug development, rna splicing 

Roche’s Genentech unit has signed a deal with Massachusetts-based firm Skyhawk Therapeutics to develop and commercialise small molecules that modulate RNA splicing.

The deal will see Skyhawk use its drug discovery platform SkyStar to discover and develop treatments for oncology and neurological disease targets.

Genentech will then have exclusive rights to develop and commercialise potential therapeutics while paying Skyhawk upfront payments and royalties.

“Genentech has long been a leader in advancing drug discovery for oncology and neurodegenerative disorders,” said Bill Haney, co-founder and chief executive officer of Skyhawk.

“We look forward to continuing to demonstrate the utility of SkyStar to discover novel RNA splicing modifiers directed to targets important in the treatment of neurodegenerative diseases and cancer. We share Genentech’s passion for transforming patients’ lives and look forward to working with the Genentech team to potentially expand the treatment options available to patients.”

Dr James Sabry, global head of Pharma Partnering, Roche, added: “Modulation of RNA splicing represents a novel approach for difficult-to-treat diseases. Skyhawk has developed unique expertise in splicing biology, and we are excited to work with their team to discover potential new medicines for patients with cancer and neurodegenerative diseases.”

Louis Goss

Related Content

Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …

Merck invests €35m in biosafety testing in Scotland

Merck has announced that it has invested €35m in biosafety testing at its sites in …

Roche building

Roche’s Evrysdi drug for SMA shown to significantly increase survival

Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) …

Latest content